trending Market Intelligence /marketintelligence/en/news-insights/trending/VmjpKh7RFv5WXPG-c8DvBg2 content esgSubNav
In This List

Pfizer's arthritis drug gets favorable vote from FDA panel

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Pfizer's arthritis drug gets favorable vote from FDA panel

Pfizer Inc. said the U.S. Food and Drug Administration's Arthritis Advisory Committee voted 10 to 1 to recommend approval of Xeljanz to treat adults with active psoriatic arthritis.

The company's supplemental new drug application for the indication is under review by the FDA, with a decision expected by December.

Xeljanz is currently approved to treat adults with moderately to severely active rheumatoid arthritis.